All In Biotech

Drug Trial Radar · NCT07662122

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

A Phase II, Randomised, Double-blind, Parallel-group, 42-week Dose-finding Trial for BI 3034701 Administered Subcutaneously Compared to Placebo in Participants With Obesity or Overweight

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 345 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

345

Actual

Start

Jun 30, 2026

Primary completion

Jun 26, 2027

Study completion Jul 10, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Obesity
  • Overweight

Interventions

  • BI 3034701Drug

    BI 3034701

  • Placebo matching BI 3034701Drug

    Placebo matching BI 3034701

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight from baseline at Week 42 [%]Time frame: Baseline and at Week 42.

Locations

55 sites in 6 countries. Site status is shown where the registry gives one.

  • Cahaba Research, Inc. - Trussville Location

    Birmingham, Alabama

  • Focus Clinical Research

    West Hills, California

  • Optimus U Corporation-Miami-69452

    Miami, Florida

  • Javara-Fayetteville-67354

    Fayetteville, Georgia

  • Monroe Biomedical Research - Louisville

    Louisville, Kentucky

  • Arcturus Healthcare - Troy Internal Medicine Research Division

    Troy, Michigan

  • StudyMetrix Research, LLC

    City of Saint Peters, Missouri

  • Clinvest Research LLC

    Springfield, Missouri

  • Centricity Research - Morehead City

    Morehead City, North Carolina

  • Accellacare-Wilmington-67123

    Wilmington, North Carolina

  • Lillestol Research, LLC

    Fargo, North Dakota

  • Tribe Clinical Research at Parkside OB-GYN, Greer

    Greer, South Carolina

  • Texas Diabetes and Endocrinology - Central Austin

    Austin, Texas

  • South Texas Research Institute - Brownsville

    Brownsville, Texas

  • South Texas Research Institute - Edinburg

    Edinburg, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • Data Point Clinical, LLC

    Kirkland, Washington

  • Rainier Clinical Research Center

    Renton, Washington

  • Allegiance Research Specialists

    Wauwatosa, Wisconsin

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Coastal Digestive Health & CDH Research Institute

    Maroochydore, Queensland, Australia

  • Southern Adelaide Diabetes and Endocrine Services (SADES)

    Oaklands Park, South Australia, Australia

  • Eastern Health-Box Hill Hospital

    Box Hill, Victoria, Australia

  • Diex Recherche (Quebec)

    Québec, Canada

  • Ocean West Research Clinic (Surrey)

    Surrey, British Columbia, Canada

  • Hilltop Medical Clinic

    Surrey, British Columbia, Canada

  • Dr. M. B. Jones Inc.

    Victoria, British Columbia, Canada

  • Apex Trials (Guelph)

    Guelph, Ontario, Canada

  • Winterberry Research Inc.

    Hamilton, Ontario, Canada

  • The Wharton Medical Clinic Clinical Trials Inc.

    Hamilton, Ontario, Canada

  • Milestone Research Inc.

    London, Ontario, Canada

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, Canada

  • Canadian Phase Onward Inc.

    Toronto, Ontario, Canada

  • Ecogene-21

    Chicoutimi, Quebec, Canada

  • THEO Medical (Montreal)

    Montreal, Quebec, Canada

  • Centre Medical Acadie (9109-0126 Quebec Inc)

    Montreal, Quebec, Canada

  • Diex Recherche (Sherbrooke Est)

    Sherbrooke, Quebec, Canada

  • Diex Recherche (Victoriaville)

    Victoriaville, Quebec, Canada

  • Huzhou Central Hospital

    Huzhou, China

  • Center Hospital of Jinan

    Jinan, China

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.